Westergren-Thorsson G, Schmidtchen A, Särnstrand B, Fransson L A, Malmström A
Department of Physiological Chemistry, University of Lund, Sweden.
Eur J Biochem. 1992 Apr 1;205(1):277-86. doi: 10.1111/j.1432-1033.1992.tb16778.x.
Human embryonic skin fibroblasts were pretreated with transforming growth factor-beta (TGF-beta) for 6 h and then labeled with [35S]sulphate and [3H]leucine for 24 h. Radiolabeled proteoglycans from the culture medium and the cell layer were isolated and separated by isopycnic density-gradient centrifugation, followed by gel, ion-exchange and hydrophobic-interaction chromatography. The major proteoglycan species were examined by polyacrylamide gel electrophoresis in sodium dodecyl sulphate before and after enzymatic degradation of the polysaccharide chains. The results showed that TGF-beta increased the production of several different 35S-labelled proteoglycans. A large chondroitin/dermatan sulphate proteoglycan (with core proteins of approximately 400-500 kDa) increased 5-7-fold and a small dermatan sulphate proteoglycan (PG-S1, also termed biglycan, with a core protein of 43 kDa) increased 3-4-fold both in the medium and in the cell layer. Only a small effect was observed on another dermatan sulphate proteoglycan, PG-S2 (also named decorin). These observations are generally in agreement with results of other studies using similar cell types. In addition, we have found that the major heparan sulphate proteoglycan of the cell layer (protein core approximately 350 kDa) was increased by TGF-beta treatment, whereas all the other smaller heparan sulphate proteoglycans with protein cores from 250 kDa to 30 kDa appeared unaffected. To investigate whether TGF-beta also influences the glycosaminoglycan (GAG) chain-synthesizing machinery, we also characterized GAGs derived from proteoglycans synthesized by TGF-beta-treated cells. There was generally no increase in the size of the GAG chains. However, the dermatan sulphate chains on biglycan and decorin from TGF-beta treated cultures contained a larger proportion of D-glucuronosyl residues than those derived from untreated cultures. No effect was noted on the 4- and 6-sulphation of the GAG chains. By the use of p-nitrophenyl beta-D-xyloside (an initiator of GAG synthesis) it could be demonstrated that chain synthesis was also enhanced in TGF-beta-treated cells (approximately twofold). Furthermore, the dermatan sulphate chains synthesized on the xyloside in TGF-beta-treated fibroblasts contained a larger proportion of D-glucuronosyl residues than those of the control. These novel findings indicate that TGF-beta affects proteoglycan synthesis both quantitatively and qualitatively and that it can also change the copolymeric structure of the GAG by affecting the GAG-synthesizing machinery. Altered proteoglycan structure and production may have profound effects on the properties of extracellular matrices, which can affect cell growth and migration as well as organisation of matrix fibres.
人胚胎皮肤成纤维细胞用转化生长因子-β(TGF-β)预处理6小时,然后用[35S]硫酸盐和[3H]亮氨酸标记24小时。从培养基和细胞层中分离出放射性标记的蛋白聚糖,并通过等密度密度梯度离心,随后进行凝胶、离子交换和疏水相互作用色谱法进行分离。在多糖链酶解前后,通过十二烷基硫酸钠聚丙烯酰胺凝胶电泳检测主要的蛋白聚糖种类。结果表明,TGF-β增加了几种不同的35S标记蛋白聚糖的产生。一种大的硫酸软骨素/硫酸皮肤素蛋白聚糖(核心蛋白约400-500 kDa)在培养基和细胞层中均增加了5-7倍,一种小的硫酸皮肤素蛋白聚糖(PG-S1,也称为双糖链蛋白聚糖,核心蛋白为43 kDa)增加了3-4倍。对另一种硫酸皮肤素蛋白聚糖PG-S2(也称为饰胶蛋白聚糖)仅观察到较小的影响。这些观察结果总体上与使用类似细胞类型的其他研究结果一致。此外,我们发现细胞层中的主要硫酸乙酰肝素蛋白聚糖(蛋白核心约350 kDa)通过TGF-β处理而增加,而所有其他蛋白核心为250 kDa至30 kDa的较小硫酸乙酰肝素蛋白聚糖似乎未受影响。为了研究TGF-β是否也影响糖胺聚糖(GAG)链合成机制,我们还对TGF-β处理细胞合成的蛋白聚糖衍生的GAG进行了表征。GAG链的大小通常没有增加。然而,来自TGF-β处理培养物的双糖链蛋白聚糖和饰胶蛋白聚糖上的硫酸皮肤素链比未处理培养物衍生的链含有更大比例的D-葡糖醛酸残基。未观察到对GAG链的4-和6-硫酸化有影响。通过使用对硝基苯基β-D-木糖苷(一种GAG合成引发剂)可以证明,TGF-β处理的细胞中链合成也增强了(约两倍)。此外,TGF-β处理的成纤维细胞在木糖苷上合成的硫酸皮肤素链比对照含有更大比例的D-葡糖醛酸残基。这些新发现表明,TGF-β在数量和质量上影响蛋白聚糖合成,并且它还可以通过影响GAG合成机制来改变GAG的共聚结构。蛋白聚糖结构和产生量的改变可能对细胞外基质性质产生深远影响,这可能影响细胞生长和迁移以及基质纤维的组织。